Reading this on a mobile device? Try our optimized mobile version here:

March 8, 2013
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
Reach Biopharmaceutical Decision-Makers with SmartBrief
You read SmartBrief, but did you know that SmartBrief publishes more than 30 unique e-newsletters for life science and health care professionals? SmartBrief delivers an engaged audience of more than a half-million business leaders, driving best-in-class click through rates and consistent reader engagement. Find out if we're reaching your target audience or contact us.
  Health Care & Policy 
  • Sequester threatens global health
    Recent breakthroughs in drug-resistant tuberculosis, malaria and HIV/AIDS were made possible with federal funding, and cuts to that funding threaten future such breakthroughs, writes Kaitlin Christenson, coalition director of the Global Health Technologies Coalition. "Without question, cuts of this magnitude will severely hamper scientific progress at [NIH and the State Department] to develop new vaccines, drugs, and other health tools against HIV/AIDS, TB, malaria, and neglected tropical infections like Chagas -— diseases that are increasingly affecting American populations," she writes. Upcoming budget negotiations present a prime opportunity to reduce cuts to scientific and public health research and to renew U.S. leadership, she writes. The Scientist online (3/6) LinkedInFacebookTwitterEmail this Story
  • Why we shouldn't mess with Medicare Part D
    Medicare Part D is working and the U.S. should avoid the temptation to fiddle with it, writes Missouri Biotechnology Association Executive Director Kelly Gillespie. Price controls and other ill-thought-out proposals would only harm a program 85% of senior enrollees are happy with. St. Louis Post-Dispatch (3/7) LinkedInFacebookTwitterEmail this Story
  • GSK seeks EU approval for diabetes drug albiglutide
    GlaxoSmithKline submitted an application to the European Medicines Agency for approval to market its diabetes drug albiglutide. The once-weekly drug belongs to the same class as Novo Nordisk's Victoza and Amylin Pharmaceuticals' Byetta and Bydureon. Yahoo/Reuters (3/7) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  Industrial & Environmental 
  • Scientists study biofuel potential of duckweed
    A scientist at Princeton University and his colleagues are looking into the biofuel potential of duckweed, according to a report in the journal Industrial and Engineering Chemistry Research. The fast-growing aquatic plant can grow in wastewater, isn't used for human consumption and can be collected more easily than algae, the researchers said. A small-scale duckweed facility could yield a cost-competitive fuel if the price of crude oil is $100 per barrel, while a bigger biorefinery could achieve competitiveness at $72-per-barrel crude oil, the researchers stated. (3/6) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Hope never abandons you, you abandon it."
--George Weinberg,
American psychologist, writer and activist

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information